Researchers Submit Patent Application, "Antisense Oligonucleotides Targeting ATXN3", for Approval (USPTO 20230054720).
In: Gene Therapy Weekly, 2023-03-17, S. 368-368
serialPeriodical
Zugriff:
"In some embodiments, the antisense oligonucleotide comprises the nucleoside base sequence and, optionally, the sugar moiety modifications, of an antisense oligonucleotide selected from the group consisting of Compound ID Nos. "In some embodiments, the antisense oligonucleotide comprises a contiguous nucleotide sequence comprising the nucleoside base sequence and, optionally, the sugar moiety modifications, of an antisense oligonucleotide selected from the group consisting of Compound ID Nos. "The invention also provides for an LNA gapmer antisense oligonucleotide, 10-30 nucleotides in length, wherein said antisense oligonucleotide comprises a contiguous nucleotide sequence 10-30 nucleotides in length, wherein the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary, to SEQ ID NO:1, wherein the antisense oligonucleotide is capable of inhibiting the expression of human ATXN3 in a cell which is expressing human ATXN3. [Extracted from the article]
Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "Antisense Oligonucleotides Targeting ATXN3", for Approval (USPTO 20230054720).
|
---|---|
Zeitschrift: | Gene Therapy Weekly, 2023-03-17, S. 368-368 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1078-2842 (print) |
Schlagwort: |
|
Sonstiges: |
|